App Mutations In Alzheimer'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
App Mutations In Alzheimer'S Disease represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications.
Mutations in the Amyloid Precursor Protein (APP) gene cause autosomal dominant familial Alzheimer's disease, providing critical insights into amyloid-beta pathogenesis.
- Gene: APP (Amyloid Precursor Protein)
- Chromosome: 21q21.3
- Inheritance: Autosomal dominant
- Mutation Count: >40 pathogenic mutations identified
- Prevalence: ~10-15% of familial AD cases
APP is a transmembrane glycoprotein with diverse physiological functions:
- Neuronal development: Promotes neurite outgrowth and synaptic formation
- Synaptic plasticity: Modmission
- ulates excitatory: BMetal homeostasis neurotransinds copper, zinc, and iron
- Cellular stress response: Activates protective pathways
APP is cleaved by three secretases:
| Secretase |
Cleavage Site |
Products |
| α-secretase |
Aβ domain (Residue 16) |
sAPPα, CTFα (non-amyloidogenic) |
| β-secretase (BACE1) |
N-terminus of Aβ |
sAPPβ, CTFβ |
| γ-secretase |
Transmembrane domain |
Aβ peptides (Aβ40, Aβ42) |
APP mutations cause AD through two primary mechanisms:
- Increased Aβ Production: Mutations near β- or γ-secretase cleavage sites
- Altered Aβ Aggregation: Mutations within the Aβ sequence affecting fibril formation
- Location: Aβ1-2 (KM→NL at positions -2/-1)
- Effect: 3-6x increased Aβ production via enhanced β-secretase cleavage
- Age of Onset: ~50-60 years
- Reference: Mullan et al., 1992
- Location: Aβ21 (A→G, "Flemish")
- Effect: Increased Aβ production, reduced aggregation
- Age of Onset: ~50-60 years
- Reference: Hendriks et al., 1992
- Location: Aβ22 (E22G, "Arctic")
- Effect: Enhanced Aβ aggregation into protofibrils
- Phenotype: Typical AD progression
- Reference: Nilsberth et al., 2001
- Location: Aβ21 (E22Q, "Dutch")
- Effect: Hereditary cerebral hemorrhage with amyloidosis (HCHWA-D)
- Phenotype: Recurrent cerebral hemorrhages, cognitive decline
- Reference: Levy et al., 1990
- Location: Aβ24 (D23N, "Iowa")
- Effect: Enhanced Aβ40 aggregation, cerebral amyloid angiopathy
- Phenotype: CAA, cerebral hemorrhage, cognitive impairment
- Reference: Grabowski et al., 2001
- Location: Aβ37 (V717I, same as London, independent)
- Effect: Increased Aβ42 production
- Reference: Matsumura et al., 1992
- Location: APP 692 (A692G, Austrian)
- Effect: Similar to Flemish, increased Aβ production
- Reference: Carter et al., 1992
- Location: APP 693 (E693G, "French")
- Effect: Arctic-like, promotes protofibril formation
- Reference: Pasalar et al., 2002
- Location: L723P (APP "Piedmont")
- Effect: Increased Aβ42/Aβ40 ratio
- Reference: Eckman et al., 1997
Individuals with Down syndrome have three copies of APP (gene dosage effect):
- Aβ accumulation: Begins in 2nd-3rd decade
- AD incidence: ~50-70% develop dementia by age 60
- Mechanism: 1.5x APP expression → increased Aβ production
- Plaque deposition: Predominantly diffuse and cored plaques
- Vascular involvement: Cerebral amyloid angiopathy (CAA) in some mutations
- Regional distribution: Cortex, hippocampus, basal ganglia
- Synaptic loss: Early and prominent
- Neurofibrillary tangles: Tau pathology follows amyloid deposition
- Neuronal death: Progressive, especially in hippocampus
- Neuroinflammation: Microglial activation around plaques
-
BACE inhibitors: Block Aβ production at source
- Failed trials: Verubecestat, Lanabecestat, Atabecestat
- Challenge: Essential BACE functions in myelination
-
γ-secretase modulators: Shift cleavage toward shorter Aβ peptides
-
Anti-Aβ antibodies: Clear existing plaques
| Mutation |
Therapeutic Implication |
| Swedish |
BACE inhibitor responsive |
| Arctic |
Anti-aggregation drugs |
| Dutch/Iowa |
CAA-focused approaches |
| All |
Anti-Aβ immunotherapies |
App Mutations In Alzheimer'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of App Mutations In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Mullan M, et al. (1992). A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nature Genetics.
- Hendriks L, et al. (1992). Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the amyloid precursor protein gene. Nature Genetics.
- Nilsberth C, et al. (2001). The 'Arctic' APP mutation (E22G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nature Neuroscience.
- Chen X, et al. (2017). APP mutations in patients with early-onset Alzheimer's disease with or without occipital calcifications. Journal of Alzheimer's Disease.
- Van Nostrand WE, et al. (2020). Familial Alzheimer's Disease Mutations in APP and PSEN2: Differential Effects on Amyloid Beta Production and Clearance. Molecular Neurobiology.